The study by Monrose et al. (2019) observed higher ALT levels exceeding two times the upper limits of normal, suggesting that it will be helpful in screening pregnant patients who are diagnosed with ICP and have a concurrent elevation of ALT to be screened for NAFLD, which was not evident in the current investigation [20]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.